The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Early Phase 1CompletedNCT00985933

AstraZeneca20 enrolled

Overview

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy Memory Impairment

Interventions

AZD8529DRUG

6 capsules by mouth 1 time 12 to 24 prior to assessments

Placebo to match AZD8529DRUG

6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Eligibility

Sex: ALLMin age: 21 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Right handed * 12th grade education or equivalent * Able to read and write English as primary language Exclusion Criteria: * History of head injury * Substance abuse or dependence * History of claustrophobia

Locations (1)

Research Site

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

fMRI

Time frame: 3

Ketamine Infusion

Time frame: 3

Secondary Outcomes

Clinician Administered Dissociative States Scale (CADSS)

Positive and Negative Syndrome Scale (PANSS)

Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.